Répertoire du corps professoral

Scale-up and validation of personalized outcome prediction model for newly diagnosed prostate cancer patients by integrating clinicopathological data and multi-task artificial
Organisme(s) subventionnaire(s): Procure Alliance
Type de financement: Subvention
Établissement tête: Université Laval
Du 17 juin 2024 au 16 juin 2025

Repurposing bicalutamide to improve the response to immune checkpoint inhibition for treatment of advanced urothelial carcinoma
Programme: UpCycle 2.1
Organisme(s) subventionnaire(s): Société de recherche sur le cancer
Type de financement: Subvention
Établissement tête: Université Laval
Du 1 août 2022 au 31 juillet 2026

Targeting sex steroids to improve the response to bladder cancer immunotherapy
Programme: Subvention Projet
Organisme(s) subventionnaire(s): Instituts de recherche en santé du Canada
Type de financement: Subvention
Établissement tête: Université Laval
Du 1 octobre 2021 au 30 septembre 2026

Financements des 2 dernières années

Projet de recherche fondamentale en vue d'assurer la gestion de la Biobanque
Organisme(s) subventionnaire(s): Fondation du CHU de Québec
Type de financement: Subvention
Établissement tête: Université Laval
Du 20 septembre 2022 au 19 septembre 2023

En route towards prebiotic clinical trials for enhancement of immunotherapies in bladder and prostate cancers
Programme: Transformational Research
Organisme(s) subventionnaire(s): Weston Family Foundation
Type de financement: Subvention
Établissement tête: Université Laval
Du 1 juin 2020 au 30 avril 2024

Jalal Laaraj, Doctorat en microbiologie-immunologie

Encadrements terminés dans les 5 dernières années

Fahimeh Aeineh Negin, Maîtrise en microbiologie-immunologie - avec mémoire

Oscar Eduardo Molina, Doctorat en biologie cellulaire et moléculaire

Publications des 5 dernières années

Subversion of infiltrating prostate macrophages to a mixed immunosuppressive tumor-associated macrophage phenotype. Clinical and translational medicine, 2022/01. Boibessot C, Molina O, Lachance G, Tav C, Champagne A, Neveu B, Pelletier JF, Pouliot F, Fradet V, Bilodeau S, Fradet Y, Bergeron A, Toren P. DOI 10.1002/ctm2.581

Identification of Morphologic Criteria Associated with Biochemical Recurrence in Intraductal Carcinoma of the Prostate. Cancers, 2021/12. Diop MK, Albadine R, Kougioumoutzakis A, Delvoye N, Hovington H, Bergeron A, Fradet Y, Saad F, Trudel D. DOI 10.3390/cancers13246243

Résumés AUQ 2021. Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2021/11. DOI 10.5489/cuaj.7674

Dimensional reduction based on peak fitting of Raman micro spectroscopy data improves detection of prostate cancer in tissue specimens. Journal of biomedical optics, 2021/11. Plante A, Dallaire F, Grosset AA, Nguyen T, Birlea M, Wong J, Daoust F, Roy N, Kougioumoutzakis A, Azzi F, Aubertin K, Kadoury S, Latour M, Leblond F. DOI 10.1117/1.jbo.26.11.116501

Using ex vivo culture to assess dynamic phenotype changes in human prostate macrophages following exposure to therapeutic drugs. Scientific reports, 2021/09. Boibessot C, Joncas FH, Park A, Berrehail Z, Pelletier JF, Gris T, Bergeron A, Toren P. DOI 10.1038/s41598-021-98903-y

Northeastern Section of the American Urological Association 73rd Annual Meeting Abstracts. Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2021/09. DOI 10.5489/cuaj.7599

Identification of Abundant and Functional dodecaRNAs (doRNAs) Derived from Ribosomal RNA. International journal of molecular sciences, 2021/09. Lambert M, Benmoussa A, Diallo I, Ouellet-Boutin K, Dorval V, Majeau N, Joly-Beauparlant C, Droit A, Bergeron A, Têtu B, Fradet Y, Pouliot F, Provost P. DOI 10.3390/ijms22189757

Omega-3 Eicosapentaenoic Acid Reduces Prostate Tumor Vascularity. Molecular cancer research : MCR, 2020/12. Gevariya N, Lachance G, Robitaille K, Joly Beauparlant C, Beaudoin L, Fournier É, Fradet Y, Droit A, Julien P, Marette A, Bergeron A, Fradet V. DOI 10.1158/1541-7786.mcr-20-0316

Long chain omega-3 fatty acids and their oxidized metabolites are associated with reduced prostate tumor growth. Prostaglandins, leukotrienes, and essential fatty acids, 2020/11. Bilodeau JF, Gevariya N, Larose J, Robitaille K, Roy J, Oger C, Galano JM, Bergeron A, Durand T, Fradet Y, Julien P, Fradet V. DOI 10.1016/j.plefa.2020.102215

Identification of a Transcriptomic Prognostic Signature by Machine Learning Using a Combination of Small Cohorts of Prostate Cancer. Frontiers in genetics, 2020/11. Vittrant B, Leclercq M, Martin-Magniette ML, Collins C, Bergeron A, Fradet Y, Droit A. DOI 10.3389/fgene.2020.550894

Northeastern Section of the AUA 72nd Annual Meeting Abstracts Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2020/09. Donnelly L, Tang J, Lian F, Higgins P, Samarakoon R, Doersch K, Abston K, Kim H, Li X, Bjazevic J, Spierling A, Al K, Razvi H, Burton J, Bjazevic J, Skog J.

Identification of intraductal carcinoma of the prostate on tissue specimens using Raman micro-spectroscopy: A diagnostic accuracy case-control study with multicohort validation. PLoS medicine, 2020/08. Grosset AA, Dallaire F, Nguyen T, Birlea M, Wong J, Daoust F, Roy N, Kougioumoutzakis A, Azzi F, Aubertin K, Kadoury S, Latour M, Albadine R, Trudel D. DOI 10.1371/journal.pmed.1003281

Androgen receptor and immune cell PD-L1 expression in bladder tumors predicts disease recurrence and survival. World journal of urology, 2020/07. Toren P, Brisson H, Simonyan D, Hovington H, Lacombe L, Bergeron A, Fradet Y. DOI 10.1007/s00345-020-03358-x

Immune-focused multi-omics analysis of prostate cancer: leukocyte Ig-Like receptors are associated with disease progression OncoImmunology, 2020/01. Benjamin Vittrant, Alain Bergeron, Oscar Eduardo Molina, Mickael Leclercq, Xavier-Philippe Légaré, Hélène Hovington, Valérie Picard, Marie-Laure Martin-Magniette, Julie Livingstone, Paul C. Boutros, Colin Collins, Yves Fradet, Arnaud Droit. DOI 10.1080/2162402X.2020.1851950